Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
872
datasets available to search
ShareScore release 0.9.0
Dataset results
872 results for “disease progression”
Raw dataset and additional data for article "Nonmotor symptoms associated with progressive loss of dopaminergic neurons in a mouse model of Parkinson's disease"
<p>Dataset from the project investigating the presence of nonmotor symptoms of Parkinson's disease in a mouse model of progressive loss of dopaminergic neurons (namely,TIF-IADATCreERT2 strain). Mice were tested for executive and cognitive functions (males: Operant Sensation Seeking test, OSS; females: Probabilistic Reversal Learning Task in Intellicages), olfactory acuity (males: buried food test), saccharin preference (males and females), and motor performance (males and females: test using CatWalk apparatus).</p><p>The dataset includes files used to perform statistical analyses but their names may vary from the ones used in the scripts. For the purpose of recreating our analyses, please refer to the GitHub page, where both scripts and input data file names (in 'Raw data files' section) are compliant: https://github.com/annaradli/tif-pd-behavior.</p><p><strong>Description of files:</strong></p><p><i>Raw data files:</i></p><ul><li>animals_info.csv - animals data: genotype, sex, age, Intellicage tag identifier</li><li>catwalk_run_statistics_all_females.csv - data recorded in CatWalk apparatus for females</li><li>catwalk_run_statistics_all_males.csv - data recorded in CatWalk apparatus for males</li><li>females_weight_raw_data_revised.csv - females' body weight (revised for containing Polish words)</li><li>intellicage_raw_data.csv - data recorded in IntelliCage exported to .csv format</li><li>intellicage_raw_data_R.RData - data recorded in IntelliCage in .RData format</li><li>males_weight_raw_data.csv - males' body weight</li><li>olfactory_time_digging_raw_data.csv - time to start digging at the right place in the buried food test</li><li>olfactory_time_retrieve_raw_data.csv- time to retrieve cracker in the buried food test</li><li>oss_raw_data.csv - data recorded in the OSS test</li><li>saccharin_preference_males_raw_data.csv - saccharin preference test results for males</li><li>snvta_cells_count.csv - number of TH+ cells in SN and VTA in male mice (3+3) 14 weeks after tamoxifen treatment</li></ul><p><i>Additional data files:</i></p><ul><li>all_anova.xlsx - summary of two-way ANOVAs of all behavioral tests and weight measurements for males and females</li><li>catwalk_complete.xlsx - CatWalk complete dataset with datapoints</li><li>catwalk_correlation_between_paws.xlsx - correlation coefficients of CatWalk parameters between the left and right paws</li><li>catwalk_reduced.xlsx - CatWalk parameters used in linear regression model reduction of data</li><li>intelli.xlsx - IntelliCage data summarized in bins</li><li>oss.xlsx - operant sensation-seeking data</li></ul><p>v2 contains the corrected 'animals_info.csv' file without an unnecessary column.</p><p>v3 has a revised version of file containing females' weight measurements and also added a file with midbrain cell counts</p><p>v4 has a whole section of 'Additional data files' added</p>
iDPP@CLEF 2022 - Participants' repositories for the Intelligent Disease Prediction Progression Challenge
<p><a href="https://brainteaser.health/open-evaluation-challenges/idpp-2022/">iDPP@CLEF 2022</a> (Intelligent Disease Progression Prediction at CLEF) is a challenge organised by the <a href="https://brainteaser.health/">BRAINTEASER</a> Horizon 2020 project and co-located with <a href="https://clef2022.clef-initiative.eu/">CLEF 2022</a> (Conference and Labs of the Evaluation Forum). </p> <p>BRAINTEASER is a data science project that seeks to exploit the value of big data, including those related to health, lifestyle habits, and environment, to support patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and their clinicians. Taking advantage of cost-efficient sensors and apps, BRAINTEASER will integrate large, clinical datasets that host both patient-generated and environmental data.</p> <p>The goal of iDPP@CLEF is to design and develop an evaluation infrastructure for AI algorithms able to:</p> <ul> <li> <p>Better describe<strong> disease mechanisms</strong>.</p> </li> <li> <p><strong>Stratify patients </strong>according to their phenotype assessed all over the disease evolution.</p> </li> <li> <p><strong>Predict disease progression</strong> in a probabilistic, time dependent fashion.</p> </li> </ul> <p>iDPP@CLEF 2022 offered the following tasks:</p> <ul> <li> <p><strong>Pilot Task 1 – Ranking Risk of Impairment</strong>: It focuses on ranking of patients based on the risk of impairment in specific domains. More in detail, we will use the ALSFRS-R scale to monitor speech, swallowing, handwriting, dressing/hygiene, walking and respiratory ability in time and will ask participants to rank patients based on time to event risk of experiencing impairment in each specific domain.</p> </li> <li> <p><strong>Pilot Task 2 – Predicting Time of Impairment</strong>: It refines Task 1 asking participants to predict when specific impairments will occur (i.e. in the correct time-window). In this regard, we assess model calibration in terms of the ability of the proposed algorithms to estimate a probability of an event close to the true probability within a specified time-window.</p> </li> <li> <p><strong>Position Papers Task 3 – Explainability of AI algorithms</strong>: We call for proposals of different visualization frameworks able to show the multivariate nature of the data and the model predictions in an explainable, possibly interactive, way.</p> </li> </ul> <p> </p> <p>This dataset contains the repositories of the participants to iDPP@CLEF 2022. These repositories contain the output, i.e. the predictions, produced by the participating systems as well as the performance scores for those systems.</p> <p>For additional information about iDPP@CLEF 2022, please see:</p> <ul> <li> <p>Guazzo, A., Trescato, I., Longato, E., Hazizaj, E., Dosso, D., Faggioli, G., Di Nunzio, G. M., Silvello, G., Vettoretti, M., Tavazzi, E., Roversi, C., Fariselli, P., Madeira, S. C., de Carvalho, M., Gromicho, M., Chiò, A., Manera, U., Dagliati, A., Birolo, G., Aidos, H., Di Camillo, B., and Ferro, N. (2022). Intelligent Disease Progression Prediction: Overview of iDPP@CLEF 2022. In Barr ́on-Cedeno, A., Da San Martino, G., Degli Es- posti, M., Sebastiani, F., Macdonald, C., Pasi, G., Hanbury, A., Potthast, M., Faggioli, G., and Ferro, N., editors, <em>Experimental IR Meets Multilinguality, Multimodality, and Interaction. Proceedings of the Thirteenth International Conference of the CLEF Association (CLEF 2022)</em>, pages 395–422. Lecture Notes in Computer Science (LNCS) 13390, Springer, Heidelberg, Germany.</p> </li> <li> <p>Guazzo, A., Trescato, I., Longato, E., Hazizaj, E., Dosso, D., Faggioli, G., Di Nunzio, G. M., Silvello, G., Vettoretti, M., Tavazzi, E., Roversi, C., Fariselli, P., Madeira, S. C., de Carvalho, M., Gromicho, M., Chiò, A., Manera, U., Dagliati, A., Birolo, G., Aidos, H., Di Camillo, B., and Ferro, N. (2022). Overview of iDPP@CLEF 2022: The Intelligent Disease Progression Prediction Challenge. In Faggioli, G., Ferro, N., Hanbury, A., and Potthast, M., editors, <em>CLEF 2022 Working Notes</em>, pages 1130– 1210. CEUR Workshop Proceedings (CEUR-WS.org), ISSN 1613-0073. <a href="https://ceur-ws.org/Vol-3180/paper-88.pdf">http://ceur-ws.org/Vol-3180/</a>.</p> </li> </ul>
Dataset related to: Add-On Cyclic Angiotensin-(1-7) with Cyclophosphamide Arrests Progressive Kidney Disease in Rats with ANCA Associated Glomerulonephritis
<p>The files contain all the dataset included in the manuscript divided by figures.</p> <p> </p> <p>Abstract: Rapidly progressive crescentic glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies (ANCA-GN) is a major cause of renal failure. Current immunosuppressive therapies are associated with severe side effects, intensifying the need for new therapeutic strategies. The activation of Mas receptor/Angiotensin-(1-7) axis exerted renoprotection in chronic kidney disease.<br> Here, we investigated the effect of adding the lanthionine-stabilized cyclic form of angiotensin-1-7 [cAng-(1-7)] to cyclophosphamide in a rat model of ANCA-GN. At the onset of proteinuria,Wistar Kyoto rats with ANCA-GN received vehicle or a single bolus of cyclophosphamide, with or without daily cAng-(1-7). Treatment with cAng-(1-7) plus cyclophosphamide reduced proteinuria by 85% vs. vehicle, and by 60% vs. cyclophosphamide, and dramatically limited glomerular crescents to less than 10%. The addition of cAng-(1-7) to cyclophosphamide protected against glomerular inflammation and endothelial rarefaction and restored the normal distribution of parietal epithelial cells. Ultrastructural analysis revealed a preserved GBM, glomerular endothelium and podocyte structure, demonstrating that combination therapy provided an additional layer of renoprotection. This study demonstrates that adding cAng-(1-7) to a partially effective dose of cyclophosphamide arrests the progression of renal disease in rats with ANCA-GN, suggesting that cAng-(1-7) could be a novel clinical approach for sparing immunosuppressants.</p>
Genome-wide determinants of mortality and clinical progression in Parkinson's disease - Summary statistics
<p>Summary statistics from "Genome-wide determinants of mortality and clinical progression in Parkinson’s disease".</p>
A more accurate risk biomarkers recognition for Progressive Multifocal Leukoencephalopathy (PML) caused by Polyomavirus JC in patients with multiple sclerosis during treatment with disease-modifying therapies (DMTs): an ongoing clinical challenge.
<p>The therapeutic scenario for the treatment of MS has recently been characterized by a veritable revolution, which has included the introduction, for the first time, of drug treatment guidelines and the entry, in the therapeutic landscape of the last decade, of numerous new drugs that, in varying but significantly relevant ways, have proven capable of modifying the course of the disease (Disease-Modifying Therapies - DMTs). <br> While the arsenal of available drugs has resulted in advances in efficacy and selectivity, it has also exposed them to the danger of side effects, potentially serious and in some cases even fatal. Among the most important side effects, complications of infectious origin, characterized by cases of viral infection/reactivation, as in the case of JCPyV, the etiologic agent of PML, are the most represented. This study, based on the follow-up of MS patients treated with different DMTs, contributes to implementing the data in the literature regarding a greater understanding of the risks related to the administration of these drugs and more appropriate monitoring of MS treatment. The risk of JCPyV reactivation with Fingolimod and Dimethyl fumarate is lower than the risk of viral reactivation associated with natalizumab.<br> In light of the data obtained, it is possible to conclude that, in the case of natalizumab, testing for JC viruria would seem to be more useful in identifying those patients with a JCPyV-specific humoral response that is not yet detectable. In addition, our results, draw attention to the importance of analyzing the NCCR rearrangements of JCPyV. Indeed, the particular rearrangements found in plasma and PBMCs of patients with RRMS treated with natalizumab could represent an alert of neuroinvasiveness in order to detect early those patients with a higher risk of developing PML. In the case of dimethyl fumarate, it seems likely that monitoring of lymphopenia would identify a higher risk group of patients in whom alternative therapy should be sought. Prolonged lymphopenia, with absolute lymphocyte counts less than 750 lymphocytes/mL, might be the major risk factor for PML although, a greater risk might lie in the loss of CD8+ cells that are crucial for JCPyV control.<br> For fingolimod, this strategy cannot be applied because the number of circulating lymphocytes decreases while the actual lymphocyte function appears largely normal therefore, monitoring viruria and viremia along with identification of the neurotrophic variant of the virus seems a more exploitable means for risk stratification.</p> <p>In conclusion, the results of this study can be considered directly transferable to the National Health System in that, both the monitoring of JCPyV reactivation by viruria and the sequence analysis of viral NCCR and host immune set-up could play the role of translatable biomarkers in clinical practice in order to assess the risk of PML onset. In addition to improving risk stratification of this disease, these biomarkers of viral reactivation and pathogenicity could facilitate timely diagnosis, optimizing the use of health care resources and contributing to the reduction of direct and indirect costs of MS disease.</p> <p>Prezioso Carla was supported by the Italian Ministry of Health (Starting Grant: SG-2018-12366194).</p>
Determinants of Disease Progression in Bangladeshi COVID-19 Patients: A Cross-sectional Survey
<p>This was a nationwide study of COVID-19 patients who were diagnosed and confirmed by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) from Nov 2020 to April 2021. The list of available COVID-19 positive patients was obtained, after formal written approval, from Civil Surgeon’s (CS) offices in Bangladesh. </p>
KidDO progress presentation 2022: Metabolic Targets for Therapeutic Intervention in Kidney Disease
<p>This is a recorded talk with head of the KidDO project - Robert Fenton - where he presents the latest project progress.</p> <p>The talk was given at one of ODIN's (the Open Discovery Innovation Network) Knowledge Sharing Events in May 2022.</p> <p> </p> <p> </p>
Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis
<p><span>Retinal optical coherence tomography has been identified as biomarker for disease progression in relapsing-remitting multiple sclerosis (RRMS), while the dynamics of retinal atrophy in progressive MS are less clear. We investigated retinal layer thickness changes in RRMS, </span><span>primary and secondary progressive MS (PPMS, SPMS)</span><span>, and their prognostic value for disease activity. Here, we analyzed 2651 OCT measurements of 195 RRMS, 87 SPMS, 125 PPMS patients, and 98 controls from five German MS centers after quality control. Peripapillary and macular retinal nerve fiber layer (pRNFL, mRNFL) thickness </span><span>predicted</span><span> future relapses in all MS and RRMS patients while mRNFL</span><span> and </span><span>ganglion cell-inner plexiform layer (GCIPL) </span><span>thickness predicted </span><span>future </span><span>MRI activity </span><span>in RRMS (mRNFL, GCIPL) and PPMS (GCIPL). mRNFL thickness </span><span>predicted </span><span>future disability progression </span><span>in PPMS.</span><span> </span><span>However, thickness change rates were subject to considerable amounts of measurement variability. In conclusion, retinal degeneration, most pronounced of pRNFL and GCIPL, occurs in all subtypes. Using the current state of technology, longitudinal assessments of retinal thickness may not be suitable on a single patient level.</span></p>
Data from: Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression
<p>Constitutive Androstane Receptor (CAR, <em>Nr1i3</em>), a liver nuclear receptor and xenobiotic sensor, induces drug, steroid and lipid metabolizing enzymes, stimulates liver hypertrophy and hyperplasia, and ultimately, hepatocellular carcinogenesis. The mechanisms linking early CAR responses to later disease development are poorly understood. Here we show that exposure of CD-1 mice to TCPOBOP, a halogenated xenochemical and selective CAR agonist ligand, induces pericentral steatosis marked by hepatic accumulation of cholesterol and neutral lipid, and elevated circulating alanine aminotransferase, indicating hepatocyte damage. TCPOBOP-induced steatosis was weaker in the pericentral region but stronger in the periportal region in females compared to males. Early (1-day) TCPOBOP transcriptional responses were enriched for CAR-bound primary response genes, and for lipogenesis and xenobiotic metabolism and oxidative stress protection pathways; late (2-wk) TCPOBOP responses included many CAR binding-independent secondary response genes, with enrichment for macrophage activation, immune response and cytokine and reactive oxygen species production. Late upstream regulators specific to TCPOBOP-exposed male liver were linked to pro-inflammatory responses and hepatocellular carcinoma progression. TCPOBOP administered weekly to male mice using a high corn oil vehicle activated carbohydrate-responsive transcription factor (MLXIPL)-regulated target genes, dysregulated mitochondrial respiratory and translation regulatory pathways, and induced more advanced liver pathology. Overall, TCPOBOP exposure recapitulates histological and gene expression changes characteristic of emerging steatotic liver disease, including secondary gene responses in liver non-parenchymal cells indicative of transition to a more advanced disease state. Upstream regulators of both the early and late TCPOBOP response genes include novel biomarkers for foreign chemical-induced metabolic dysfunction-associated steatotic liver disease.</p>
Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression.
<p>This file contains vst-normalized gene expression data along with annotations which can be used to reproduce our findings.</p>
Evolution of Endometriosis Lesions Followed by Ultrasound and Quality of Life of Patients: Factors That Influence Disease Progression in a Prospective Cohort
ClinicalTrials.gov study NCT07282990. IPD Sharing: YES. Countries: 1. Publications: 15.
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)
ClinicalTrials.gov study NCT00500682. IPD Sharing: Not stated. Countries: 12. Publications: 3.
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine
ClinicalTrials.gov study NCT01300546. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Predicting Disease Progression and/or Recurrence in Cancer
ClinicalTrials.gov study NCT04776837. IPD Sharing: YES. Countries: 1. Publications: 0.
Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant
ClinicalTrials.gov study NCT03862807. IPD Sharing: YES. Countries: 7. Publications: 3.
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
ClinicalTrials.gov study NCT01917721. IPD Sharing: NO. Countries: 1. Publications: 1.
Remotely Supervised tDCS for Slowing ALS Disease Progression
ClinicalTrials.gov study NCT04866771. IPD Sharing: NO. Countries: 1. Publications: 1.
A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)
ClinicalTrials.gov study NCT00501046. IPD Sharing: Not stated. Countries: 12. Publications: 3.
Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)
ClinicalTrials.gov study NCT00078403. IPD Sharing: Not stated. Countries: 2. Publications: 12.
Effect of Pioglitazone on Insulin Resistance, Atherosclerosis Progression and Clinical Course of Coronary Heart Disease
ClinicalTrials.gov study NCT03011775. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.